Mayo Clinic: Glioblastoma trials

The registry lists 23 Glioblastoma studies with Mayo Clinic as lead sponsor. 11 are open to participants now and 3 have results posted.

Early Phase 1 4Phase 1 6Phase 2 8Phase 4 1No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype GlioblastomaRecruitingNCT07708961Phase 2
• Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade GliomasRecruitingNCT07468136Phase 1/2
• GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 AstrocytomaRecruitingNCT07301268Phase 2
• The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding AreasRecruitingNCT07285044Phase 2
• Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With GlioblastomaRecruitingNCT07091864Not applicable
• A Study for Cerebral Open Flow MicroperfusionNot yet recruitingNCT07089758Not applicable
• Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or Recurrent GlioblastomaRecruitingNCT07076472Early Phase 1
• A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma, GHoST TrialRecruitingNCT07074756Not applicable
• ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade GliomaRecruitingNCT05917145Phase 1
• Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing CraniotomyRecruitingNCT05789394Phase 1
• Feasibility of Intra- and Post-operative Microdialysis During Neurosurgery for Central Nervous System LesionsRecruitingNCT04047264Not applicable
• 18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation TherapyCompletedNCT03778294Phase 2Results posted
• Pembrolizumab and Standard Therapy in Treating Patients With GlioblastomaActive, not recruitingNCT03197506Phase 2Results posted
• Viral Therapy in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT00390299Phase 1Results posted
• Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral ChemotherapyCompletedNCT06625047Phase 4
• Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA StudyActive, not recruitingNCT05781321Phase 2
• Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent GlioblastomaActive, not recruitingNCT05465954Phase 2
• Early Integration of Palliative Care Using the BEACON PROQOL in Patients With High Grade Glioma and Their CaregiversCompletedNCT04630379Not applicable
• WSD0922-FU for Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System MetastasesActive, not recruitingNCT04197934Phase 1
• Vaccine Therapy in Treating Patients With Recurrent GlioblastomaCompletedNCT03360708Early Phase 1
• Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain TumorsCompletedNCT02444546Phase 1
• Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed GlioblastomaCompletedNCT01957956Early Phase 1
• Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant GliomaCompletedNCT01165632Early Phase 1